Key result
Hemodynamic response linked to ~43-point higher 8-year survival compared to nonresponse in portal hypertension.
Cohort (n=105)
Answers are grounded in this paper and cite their sources.
Demonstrates that lowering hepatic venous pressure gradient reduces clinical complications and improves survival in cirrhosis, indicating the prognostic value of hemodynamic response targets.
In cirrhotic patients under pharmacologic treatment for portal hypertension, a reduction in hepatic venous pressure gradient (HVPG) of >or=20% of baseline or to <or=12 mm Hg markedly reduces the risk of variceal rebleeding. This study was aimed at evaluating whether these hemodynamic targets also prevent other complications of portal hypertension and improve long-term survival. One hundred five cirrhotic patients included in prospective trials for the prevention of variceal rebleeding were studied. Seventy-three of the patients had 2 separate HVPG measurements, at baseline and under pharmacologic therapy with propranolol +/- isosorbide mononitrate. Patients were followed for up to 8 years. Survival and risk of developing portal hypertension-related complications were compared between responders and nonresponders. Twenty-eight patients showed a reduction of HVPG >or=20% of baseline or to <or=12 mm Hg (responders), and 45 patients were nonresponders. Nonresponders had a significantly greater risk of developing variceal rebleeding (P =.013), ascites (P =.025), spontaneous bacterial peritonitis (P =.003), hepatorenal syndrome (P =.026), and hepatic encephalopathy (P =.024) than responders. Eight-year cumulative probability of survival was significantly lower in nonresponders than in responders (52% vs. 95%, respectively, P =.003). At multivariate analysis, being a nonresponder was independently associated with the risk of developing rebleeding, ascites, spontaneous bacterial peritonitis, and lower survival. In conclusion, in cirrhotic patients receiving pharmacologic treatment for prevention of variceal rebleeding, a decrease in HVPG >or=20% or to <or=12 mm Hg is associated with a marked reduction in the long-term risk of developing complications of portal hypertension and with improved survival.
No takes yet. Share an insight, caveat, or question.
Juan G. Abraldeṣ (2003) conducted a cohort in Cirrhosis with portal hypertension (n=105). Hemodynamic response (HVPG reduction >=20% of baseline or to <=12 mm Hg) on propranolol +/- isosorbide mononitrate vs. Hemodynamic nonresponders was evaluated on 8-year cumulative probability of survival (p=0.003). Hemodynamic response improved 8-year cumulative survival compared with nonresponse and reduced portal hypertension complications.
Synapse has enriched 10 related papers. Consider them for comparative context: